PDCD1 and non-small cell lung carcinoma: Particularly in comparison to pembrolizumab monotherapy, the combination of a humanized monoclonal antibody pembrolizumab and platinum-based chemotherapy against PD-1 significantly enhanced the total survival of NSCLC patients, with PD-L1 ≥ 50% and negligible to gene mutations in the ALK and EGFR genes [132].